Butterfly Medical
PrivateLast Round
Series C
May 14, 2026
Total Funding Raised
$30.06M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Butterfly Medical operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Series C round in May 2026.
Butterfly Medical is a therapeutic devices company that has developed a proprietary, non-surgical, and minimally invasive solution for the treatment of benign prostatic hyperplasia (BPH).
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Butterfly Medical Comparables
Compare Butterfly Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zenflow | 91% | |
| Rivermark Medical | 91% | |
| ProVerum Medical | 90% |
For institutional investors. Book with your work email.
Butterfly Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 14, 2026 | ||||
| Series B | Oct 6, 2020 | ||||
| Angel | Jan 29, 2020 | ||||
| Grant | Sep 1, 2019 | ||||
| Seed | Oct 1, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Butterfly Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series C |
| MedVenture Partners | Series C |
| Junson Capital | Series C |
| New Rhein Healthcare Investors | Series C, Series B |
| MassChallenge Israel | Grant |
| MedVenture Partners, Inc. | Series C |
| Wasatch Health | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 63% MoM.
- Jul 24, 2026
Monthly visitors grew 99% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 13, 2026
Butterfly Medical Ltd. presents a company update at the 2026 AdvaMed MedTech Conference on Oct 20th '26, at 9:15 a.m. ET on the Innovation Pavilion Stage in Massachusetts.
For institutional investors. Book with your work email.
Butterfly Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Butterfly Medical's valuation, stock price, and market status.
Is Butterfly Medical a public or private company?
Butterfly Medical is a private company.
What is the current stock price of Butterfly Medical?
Butterfly Medical is a private company, so its shares have no public market price. Caplight tracks Butterfly Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Butterfly Medical worth (valuation)?
Valuation information for Butterfly Medical is not publicly available.
Can I buy Butterfly Medical stock?
Butterfly Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Butterfly Medical's last funding round?
Butterfly Medical's most recent funding round was Series C on May 14, 2026.
Who are the main investors in Butterfly Medical?
Key investors in Butterfly Medical include New Rhein Healthcare Investors, MassChallenge Israel.
Will Butterfly Medical IPO soon?
No public IPO plans have been announced for Butterfly Medical.
How can I track Butterfly Medical secondary market activity?
Caplight tracks bids, offers, and trades in Butterfly Medical's shares on secondary markets.